Healthcare firm Azenta beats Q4 revenue, profit estimates

Overview

• Azenta fiscal Q4 revenue grows 6% yr/yr, beating analyst expectations

• Adjusted EPS for fiscal Q4 beats consensus, indicating improved operational performance

• Company achieves significant adjusted EBITDA margin expansion, reflecting effective cost management

Outlook

• Azenta expects FY26 organic revenue growth of 3% to 5%

• Company anticipates FY26 adjusted EBITDA margin to expand by 300 basis points

Result Drivers

• MULTIOMICS GROWTH - Revenue in Multiomics increased 11% yr/yr, driven by Next Generation Sequencing and Gene Synthesis

• SAMPLE MANAGEMENT - Sample Management Solutions revenue grew 2% yr/yr, driven by Clinical Biostores and Automated Stores

• OPERATIONAL EFFICIENCY - Margin expansion attributed to operational improvements and cost discipline

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Azenta Inc is $35.00, about 14.3% above its November 20 closing price of $30.00

• The stock recently traded at 39 times the next 12-month earnings vs. a P/E of 45 three months ago

Press Release: ID:nPn152Dr1a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)